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nonneoplastic cells) occurred in 55 ICCs (26%). BAP1 loss predicted a
strong trend toward improved median survival of 40.80 months (95%
CI, 28.14–53.46) versus 24.87 months (95% CI, 18.73–31.01),
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Abstract: BRCA1-associated protein 1 (BAP1) is a deubiquitinating
enzyme that functions as a tumor suppressor gene. Double hit BAP1
inactivation has been reported in a range of tumor types, including
intrahepatic cholangiocarcinoma (ICC), sometimes in association with
germline mutation.
We performed immunohistochemistry for BAP1 on a well-charac-
terized cohort of 211 ICC patients undergoing surgical resection with
curative intent at 3 institutions based in 3 different countries. The
median age at diagnosis was 65 years (range, 36.5–86) and 108
(51%) were men. Negative staining for BAP1 (defined as completely
absent nuclear staining in the presence of positive internal controls inher, MD, Nicola S
, MD, and Anthony J. Gill, MD, FRCPA
P¼ 0.059). In a multivariate model including age, sex, BAP1 status,
tumor stage, tumor grade, lymphovascular invasion, and tumor size,
female sex was associated with improved survival (hazard ratio [HR]
0.54; 95% CI, 0.34–0.85), while advanced tumor stage and lympho-
vascular invasion (HR 1.89; 95% CI, 1.09–3.28) correlated with
decreased survival. In a multivariate analysis, high grade tumors were
associated with BAP1 loss (odds ratio [OR] 3.32; 95% CI, 1.29–8.55),
while lymphatic invasion was inversely associated with BAP1 loss (OR
0.36; 95% CI, 0.13–0.99).
In conclusion, we observed a trend toward improved prognosis in
ICC associated with absent expression of BAP1 and an association of
BAP1 loss with higher histological grade and absent lymphatic invasion.
Female sex was associated with improved survival while advanced
tumor stage and lymphatic invasion were associated with decreased
survival.
(Medicine 95(2):e2491)
Abbreviations: BAP1 = BRCA1-associated protein 1, HR = hazard
ratio, ICC = intrahepatic cholangiocarcinoma, IHC =
immunohistochemistry, TMA = tissue microarray, TMA = tissue
microarray.
INTRODUCTION
BRCA1-associated protein 1 (BAP1) is a nuclear deubiqui-tinating enzyme in the ubiquitin C-terminal hydrolase
family.1,2 It is encoded by the BAP1 gene at 3p21.1 and together
with other genes such as ARID1A and PBRM1, is involved in
chromatin remodeling.1,3 BAP1 behaves as a true tumor sup-
pressor gene and appears to follow a classic Knudson two-hit
model.1 That is, germline BAP1 mutation is associated with a
newly recognized autosomal-dominant hereditary cancer syn-
drome, (OMIM #6143), characterized by uveal melanoma,
mesothelioma, cutaneous melanocytic lesions, renal cell carci-
noma, basal cell carcinoma, and intrahepatic cholangiocarci-
noma (ICC);4–7 while biallelic inactivations including somatic
mutations or deletions have also been reported in a range of
tumors including uveal melanoma, mesothelioma, cutaneous
melanocytic neoplasms, and clear cell renal carcinoma.6–14
Cholangiocarcinoma is a relatively rare malignancy of
biliary epithelium, with a reported annual incidence of 8 per
million in the United States.15 It accounts for approximately 3% of
gastrointestinal cancers and is the second most common primarycy after hepatocellular carcinoma.16,17
may be classified as either intrahepatic
factors for cholangiocarcinoma include
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primary sclerosing cholangitis, liver fluke infestation, bile duct
anomalies, biliary papillomatosis, chemical carcinogens includ-
ing thorotrast and nitrosamines, obesity, nonalcoholic liver dis-
ease, and viral hepatitis.18,19 However, the majority of
cholangiocarcinomas, at least in Western countries where liver
fluke infection is rare, arise in the absence of predisposing
factors.18–20 The outlook for cholangiocarcinoma is generally
poor, with an overall 5-year survival of less than 5%.15
It has recently been suggested that germline BAP1
mutations predispose to intrahepatic cholangiocarcinoma5
and somatic biallelic inactivating BAP1 mutations have been
reported in up to 25% of intrahepatic cholangiocarcinomas
(ICC).3,5,21 Immunohistochemistry (IHC) for BAP1 appears
to be a reliable marker of double hit inactivation of BAP1 in
mesothelioma and melanoma 1,22–25 and phenotype–genotype
correlations are rapidly emerging in both melanoma and
mesothelioma. For example, in uveal melanoma loss of
BAP1 expression is a strong predictor of adverse outcome,23,24
whereas in mesothelioma BAP1 loss is associated with a distinct
phenotype of female sex, younger age onset, epithelioid
morphology, and improved prognosis.1,22,25 Additionally,
BAP1 loss in cells obtained by effusion cytology has been
proposed as an adjunct to support a diagnosis of mesothelioma
in select patients.26 However, to date, there has been no
systematic study of BAP1 expression in ICC.
We therefore sought to investigate the clinical and patho-
logical features associated with loss of expression of BAP1 as
determined by IHC in a large multiinstitutional cohort of ICC
specifically to explore if there are phenotype–genotype corre-
lations for BAP1 loss in cholangiocarcinoma.
METHODS
Andrici et alThe computerized databases of the departments of ana-
tomical pathology Royal North Shore Hospital, Sydney, Aus-
tralia; University Hospital Heidelberg, Heidelberg, Germany;
FIGURE 1. Serial H&E (A, C) and BAP1 IHC (B, D) stained sections from
nuclear staining in both the neoplastic and nonneoplastic cells (origi
2 | www.md-journal.comand University and Hospital Trust of Verona, Verona, Italy were
searched for cases of definite intrahepatic cholangiocarcinoma
diagnosed between January 1990 and August 2014. Cases
where metastasis to the liver or primary pancreaticobiliary or
extrahepatic origin were considered possible were excluded, as
were cases in which no diagnostic material remained in for-
malin fixed paraffin embedded blocks. All cases were indepen-
dently reviewed by experienced gastrointestinal pathologists to
confirm the diagnosis of ICC and to restage according to the 7th
edition 2009 AJCC staging system.27
A tissue microarray (TMA) containing duplicate 1-mm
cores of formalin fixed paraffin embedded tumor tissue was
constructed for the cases from Royal North Shore Hospital and
Verona. For the cases from Heidelberg, whole sections were
used. Immunohistochemistry (IHC) for BAP1 was performed
on the TMA sections and whole slides using a mouse mono-
clonal anti-BAP1 antibody (clone C-4, cat no sc-28383, Santa
Cruz Biotechnology, Dallas, Texas USA, dilution 1:100). The
slides were stained on the Leica Microsystems Bond III auto-
stainer (Leica Microsystems, Mount Waverley, Victoria, Aus-
tralia) after heat-induced antigen retrieval for 30 minutes at
978C in themanufacturer’s alkaline retrieval solution ER2 (VBS
part no: AR9640). A biotin-free polymer-based detection sys-
tem (Define, VBS part no: DS 9713) was employed.
BAP1 staining was interpreted by a single observer (AG)
who was blinded to all clinical and other data at the time of
assessment. Negative staining was defined as completely absent
nuclear staining in all neoplastic cells in the presence of a
positive internal control (nonneoplastic cells such as lympho-
cytes or stromal cells), as illustrated in Figure 1. Positive
staining was defined as positive nuclear staining in any neo-
plastic cells (arbitrarily defined as greater than 2% of any
Medicine  Volume 95, Number 2, January 2016definitely neoplastic cells) as illustrated in Figure 2. If the
staining could not be interpreted on the TMA sections, due
to insufficient material or the absence of an internal positive
an intrahepatic cholangiocarcinoma demonstrating diffuse strong
nal magnifications A, B 100, C, D 400).
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
Statistical significance was defined as P< 0.05. This study was
FIGURE 2. Serial H&E (A, C) and BAP1 IHC (B, D) stained sections from an intrahepatic cholangiocarcinoma that shows completely
dot
ol (
Medicine  Volume 95, Number 2, January 2016 BAP1 in Cholangiocarcinomacontrol, the result was considered indeterminate and repeated on
whole mount sections (n¼ 5 cases). Cytoplasmic staining was
considered nonspecific and disregarded (Figure 3). That is cases
which demonstrated cytoplasmic staining only with negative
nuclear staining were considered negative.
Overall survival time was obtained from medical records
and publicly available death notices. Survival was calculated by
Kaplan–Meier analysis and compared using the log-rank test.
Characteristics of patients from the 3 cohorts, as well as those of
BAP1 negative and BAP1 positive patients, were compared
using Fischer exact test or Pearson x2 to calculate P values for
categorical variables, or the Mann–Whitney test for age, sur-
vival, and tumor size. Univariate regression analysis examined
negative IHC staining for BAP1. In this case, the nonneoplastic en
preserved positive staining and serve as an internal positive contrthe impact of each variable individually on overall survival.
Multivariate Cox regression proportional hazards analysis was
then used to explore the effect of BAP1 status on overall
FIGURE 3. Serial H&E (A) and BAP1 IHC (B) stained sections from an in
completely negative nuclear staining for BAP1 with preserved positiv
heads) which serve as an internal positive control. In this case, ther
nonneoplastic cells. For the purposes of interpreting BAP1 IHC, this cy
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.survival, adjusted for age at diagnosis, sex, stage, lymphatic
invasion, vascular invasion, tumor grade, and tumor size. Stat-
istical analyses were performed using IBM SPSS Statistics v22.
helial cells (arrows) and lymphocytes (arrowheads) demonstrated
original magnifications A, B 100, C, D 400).approved by the Northern Sydney Local Health District medical
ethics review board.
RESULTS
The study group included 211 patients with confirmed
intrahepatic cholangiocarcinoma who underwent surgery with
curative intent, comprising 49 patients from the Australian
cohort, and 81 patients each from the Italian and German
cohorts. The clinical and pathological details are summarized
in Table 1. Briefly, the mean age at diagnosis was 65 years
(range, 36.5–86 years) and 108 (51%) were men. The median
trahepatic cholangiocarcinoma. The neoplastic cells demonstrate
e staining for endothelial cells (arrows) and lymphocytes (arrow-
e is nonspecific cytoplasmic staining in both the neoplastic and
toplasmic staining is ignored (original magnification A, B 400).
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FIGURE 4. Kaplan–Meier survival curves demonstrate a trend
Medicine  Volume 95, Number 2, January 2016survival was 29.37 months (95% confidence interval [CI],
21.61–37.13 months). Loss of BAP1 expression was present
in 55 (26%) patients. There were some differences between the
toward improved survival in BAP1 IHC negative cholangiocarci-
noma (P¼0.059).3 cohorts from the different centres. The mean age of the
German cohort was younger (62 years) than the Australian
(76 years) or Italian (66 years) cohorts, P< 0.001. Patients in
TABLE 2. Univariate (n¼211) and Multivariate (n¼162) Analys
Variable
Univariable Cox
HR (95% CI),
Age at diagnosis 0.998 (0.98–1.01
Sex
Male 1.00
Female 0.81 (0.58–1.12
BAP1 status
BAP1 positive 1.00
BAP1 loss 0.69 (0.46–1.02
Stage
Stage 1 1.00
Stage 2 1.70 (1.04–2.79
Stage 3 2.67 (1.58–4.5)
Stage 4 2.40 (1.32–4.37
Grade
Grade 1 or 2 1.00
Grade 3 1.68 (1.10–2.57
Lymphatic invasion
No lymphatic invasion 1.00
Lymphatic invasion 1.84 (1.29–2.62
Vascular invasion
No vascular invasion 1.00
Vascular invasion 1.49 (1.02–2.19
Tumor size 0.999 (0.995–1.0
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.the German cohort also had larger tumors (mean, 70 mm) than
patients in the Australian (50 mm) and Italian (45 mm) cohorts,
P¼ 0.001. Lymphatic invasion was more prevalent in the
Italian (37%) and German (40%) cohorts, compared with the
Australian cohort (18%).
The Kaplan–Meier survival curves by BAP1 status for the
entire cohort are presented in Figure 4. The median overall
survival for the cohort was 29.37 months (95% CI, 21.61–37.13
months). BAP1 IHC positive ICCs demonstrated worse median
survival, 24.87 months (95% CI, 18.73–31.01 months), com-
pared with BAP1 IHC negative cases, 40.80 months (95% CI,
28.14–53.46 months), but this did not reach statistical signifi-
cance (P ¼ 0.059). Multivariate analysis in a model which
included age, sex, BAP1 status, tumor stage, tumor grade,
lymphatic invasion, vascular invasion, and tumor size
(Table 2) found only a slight trend toward increased survival
associated with loss of BAP1 expression, which was not stat-
istically significant (HR 0.89; 95% CI, 0.55–1.45; P ¼ 0.645).
The multivariable model only included the Italian and German
cohorts (n¼ 162), as the Australian cohort was missing data on
grade and vascular invasion. Female sex predicted better sur-
vival outcomes (HR 0.54; 95% CI, 0.34–0.85; P¼ 0.007),
whereas Stage 2 tumors (HR 2.19; 95% CI, 1.12–4.27;
P¼ 0.022), Stage 3 tumors (HR 2.68; 95% CI, 1.27–5.65;
P¼ 0.010), Stage 4 tumors (HR 2.95; 95% CI, 1.11–7.89;
P¼ 0.031), and lymphatic invasion (HR 1.89; 95% CI, 1.09–
3.28; P¼ 0.023) correlated with decreased patient survival
(Table 3). High grade tumors (HR 1.68; 95% CI, 1.10–2.57;
P¼ 0.017) and vascular invasion (HR 1.49; 95% CI, 1.02–2.19;
P¼ 0.039) were associated with decreased survival on univari-
BAP1 in Cholangiocarcinomaate regression, but not in the multivariate analysis.
Tables 3 and 4 summarize patient characteristics by BAP1
status. On univariate analysis, patients with BAP1 loss were less
is for Cholangiocarcinoma Patients for Overall Survival
Regression
P Value
Multivariable Cox
Regression HR (95% CI)
P Value
), 0.849 0.996 (0.98–1.02), 0.667
1.00
), 0.199 0.54 (0.34–0.85), 0.007
1.00
), 0.061 0.89 (0.55–1.45), 0.645
1.00
), 0.035 2.19 (1.12–4.27), 0.022
, <0.001 2.68 (1.27–5.65), 0.010
), 0.004 2.95 (1.11–7.89), 0.031
1.00
), 0.017 1.56 (0.97–2.50), 0.066
1.00
), 0.001 1.89 (1.09–3.28), 0.023
1.00
), 0.039 0.71 (0.44–1.01), 0.171
03), 0.647 1.00 (0.998–1.003), 0.157
www.md-journal.com | 5,
TABLE 3. Patient Characteristics by IHC Staining
Total Cohort
(n¼ 211)
BAP1 IHC Negative
(n¼ 55)
BAP1 IHC Positive
(n¼ 156) P Value
Age at diagnosis, mean (range) 65 (36.5–86) 62.5 (37–83) 66 (36.5–86) 0.243
Sex 0.212
Male, n (%) 108 (51) 24 (44) 84 (54)
Female, n (%) 103 (49) 31 (56) 72 (46)
Survival in months, median (range) 29.37 (21.61–37.13) 40.80 (28.14–53.46) 24.87 (18.73–31.01)
Stage 0.008
Stage 1 42 (20) 15 (27) 27 (17)
Stage 2 82 (39) 28 (51) 54 (35)
Stage 3 53 (25) 8 (15) 45 (29)
Stage 4 34 (16) 4 (7) 30 (19)
Grade 0.21
Grade 1 12 (7) 2 (4) 10 (8)
Grade 2 113 (70) 28 (64) 85 (72)
Grade 3 37 (23) 14 (32) 23 (20)
Lymphatic invasion 0.02
No lymphatic invasion, n (%) 132 (63) 43 (87) 89 (60)
Lymphatic invasion, n (%) 71 (34) 12 (22) 59 (40)
Vascular invasion 0.376
No vascular invasion, n (%) 71 (44) 22 (50) 49 (42)
Vascular invasion, n (%) 91 (56) 22 (50) 69 (68)
Andrici et al Medicine  Volume 95, Number 2, January 2016likely to present with more advanced tumors—Stage 3 tumors
(odds ratio [OR] 0.32; 95% CI, 0.12–0.85; P¼ 0.023), Stage 4
tumors (OR 0.24; 95% CI, 0.07–0.81; P¼ 0.022)—or with
lymphatic invasion (OR 0.42; 95% CI, 0.21–0.86; P¼ 0.018).
A small but statistically significant association between BAP1
Tumor size, median, mm (range) 54 (5–200)ss and tumor size (OR 1.01; 95% CI, 1.003–1.02; P¼ 0.0008)
as also observed on univariate analysis. On multivariate
nalysis, however, only the inverse relationship with lymphatic
DISCUSISON
Here we report, for the first time, the incidence of negative
staining for BAP1 in intrahepatic cholangiocarcinoma and the
ABLE 4. Univariate and Multivariate Analysis for Associations Between Clinicopathological Characteristics and BAP1 loss
ariable
Univariate Logistic Regression
OR (95% CI), P Value
Multivariable Logistic Regression
OR (95% CI), P Value
ge at diagnosis 0.98 (0.96–1.01), 0.242 0.993 (0.957–1.03), 0.715
ex
Male 1.00 1.00
Female 1.51 (0.81–2.80), 0.194 1.66 (0.74–3.71), 0.219
tage
Stage 1 1.00 1.00
Stage 2 0.99 (0.43–2.03), 0.862 1.04 (0.35–3.08), 0.942
Stage 3 0.32 (0.12–0.85), 0.023 0.53 (0.14–2.00), 0.347
Stage 4 0.24 (0.07–0.81), 0.022 0.51 (0.72–3.59), 0.498
rade
Grade 1 or 2 1.00 1.00
Grade 3 1.93 (0.88–4.21), 0.100 3.32 (1.29–8.55), 0.013
ymphatic invasion
No lymphatic invasion 1.00 1.00
Lymphatic invasion 0.42 (0.21–0.86), 0.018 0.36 (0.13–0.99), 0.049
ascular invasionlo
w
a
T
V
A
S
S
G
L
V
No vascular invasion 1.00
Vascular invasion 0.71 (0.35–1.42), 0
Tumor size 1.01 (1.003–1.02),
6 | www.md-journal.cominvasion remained statistically significant (OR 0.36; 95% CI,
0.13–0.99; P¼ 0.049). The multivariate analysis also found
higher histological grade to be positively associated with BAP1
loss (OR 3.32; 95% CI, 1.29–8.55; P¼ 0.013).
65 (15–200) 50 (5–175) 0.0071.00
.3335 0.93 (0.37–2.32), 0.874
0.008 1.01 (1.00–1.02), 0.059
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
results of a multivariate analysis on the impact of BAP1 loss on
overall survival. Our study included 211 cholangiocarcinoma
cases from 3 major institutions in 3 different countries and
diagnosed by experienced GIT pathologists. We demonstrate
that complete loss of staining for BAP1 occurs in 26% of
intrahepatic cholangiocarcinomas. Although our study was
not intended or designed to assess the sensitivity and specificity
of BAP1 IHC for BAP1 mutation, our incidence of negative
staining for BAP1 is very similar to the rate of inactivating
mutations reported by Jiao et al3 (25%) and Chan-On et al21
(22.2%), suggesting that loss of IHC staining for BAP1 is likely
to correlate strongly with BAP1 mutation in ICC as it has been
proven to do in mesothelioma and uveal melanoma.1,22,24–27
On univariate analysis, patients with BAP1 loss were less
likely to present with more advanced tumors—Stage 3 tumors
(OR 0.32; 95% CI, 0.12–0.85; P¼ 0.023), Stage 4 tumors (OR
0.24; 95% CI, 0.07–0.81; P¼ 0.022) or with lymphatic inva-
sion (OR 0.42; 95% CI, 0.21–0.86; P¼ 0.018), but were more
likely to present with larger tumors (OR 1.01; 95% CI, 1.003–
1.02; P¼ 0.0008). On multivariate analysis, only association
with lymphatic invasion remained statistically significant, while
an association between higher histological grade and BAP1 loss
gained statistical significance (OR 3.32; 95% CI, 1.29–8.55;
P¼ 0.013). It is also interesting to note that BAP1 loss demon-
strated some association (albeit not statistically significant) with
female sex (OR 1.66; 95% CI, 0.74–3.71; P¼ 0.219) and
younger age (OR 0.99; 95% CI, 0.96–1.03; P¼ 0.715). There
was also a strong trend toward prolonged survival in BAP1 IHC
negative cases (median survival of 40.80 months (95% CI
28.14–53.46 months) versus 24.87 months (95% CI 18.73–
31.01 months) for BAP1 IHC positive cases, but this just failed
to reach statistical significance (P¼ 0.059). This is in contrast to
melanoma where BAP1 loss is significantly associated with
worse prognosis,23,24 but similar to mesothelioma where BAP1
loss is associated with improved overall prognosis.25 Presum-
ably this indicates that pathways other than those associated
with BAP1 mutation are more lethal in mesothelioma but less
lethal that BAP1 associated pathways in uveal melanoma.
It is also interesting to note that BAP1 loss is associated on
multivariate analysis with tumors of higher histological grade
and larger tumor size yet trended toward improved survival. We
and others have previously demonstrated that in mesothelioma,
BAP1 loss is associated with the epithelioid histologic sub-
type,25,26,28 and it is possible that in cholangiocarcinoma there
may exist an association between BAP1 status and a
morphology which includes solid more solid tumors which
would be interpreted as higher grade. However on review of
our BAP1 IHC negatives cases, we were unable to identify any
distinctive morphological features. Our finding of some associ-
ation between BAP1 loss and improved survival is in contrast
with Jiao et al,3 who reported better 3-year survival rates among
BAP1 wild-type cholangiocarcinoma patients. However, we
note that their findings did not reach statistical significance,
they did not perform BAP1 IHC and that their study cohort was
significantly smaller than ours (n¼ 32 vs n¼ 211).
The frequent finding of loss of BAP1 expression in ICC
has several implications. First, it may be diagnostically import-
ant for surgical pathologists. It can be difficult to distinguish
metastatic adenocarcinoma to the liver from primary intrahe-
patic cholangiocarcinoma as there are no specific IHC markers
for primary ICC. Loss of IHC staining for BAP1 which occurred
Medicine  Volume 95, Number 2, January 2016in 26% of ICC in our study could potentially be used to support a
diagnosis of ICC when a patient presents with a liver lesion and
the differential diagnosis is between metastatic carcinoma and
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to be the only other tumor with glandular or gland-like differ-
entiation which shows a significant incidence of BAP1
loss)25,26,28 can be excluded by other means.
It has been suggested that ICC may be a component of the
hereditary cancer syndrome associated with germline BAP1
mutations.5 Therefore, it is possible that IHC for BAP1 may
play a role in triaging formal genetic testing for germline BAP1
mutation in patients presenting with cholangiocarcinoma. That
is, if a tumor shows positive staining for BAP1 then germline
BAP1 mutation can be considered unlikely, whereas if a tumor
shows negative staining for BAP1 then BAP1 mutation is not
excluded and formal counselling and genetic testing may be
warranted in patients considered at high risk for hereditary
disease for example due to onset at a young age or a family
history of BAP1-associated malignancy such as mesothelioma,
uveal melanoma, or cholangiocarcinoma. The incidence of
germline BAP1 mutations in cholangiocarcinoma is not cur-
rently known; however, the incidence of germline BAP1
mutations in malignancies such as mesothelioma and metasta-
sising uveal melanoma has been estimated at 1 to 2% or
less.22,27 It is likely that the rate of germline BAP1 mutations
to be lower in cholangiocarcinoma than that found in mesothe-
lioma and uveal melanoma, given that somatic mutations
resulting in BAP1 loss occur in approximately half of mesothe-
liomas1,22,28,29 and in up to 84% of uveal melanomas,30 which is
higher than the rate of BAP1 loss so far reported in cholangio-
carcinoma.3,21,31 Given that real rate of germline BAP1
mutations is likely to be less than 1%, it is reasonable that formal
genetic testing for BAP1 mutation be reserved for those patients
who are considered high-risk based on family and personal
history and demonstrate loss of BAP1 expression by IHC.
We observed a statistically significant association between
female sex, lymphatic invasion, and tumor stage and survival.
However, despite our large cohort our study might not be
sufficiently powered to observe other potential relationships,
especially when analyzing subgroups. The subgroup of BAP1-
negative patients, for example, only consisted of 55 patients.
We combined in our analyses cholangiocarcinoma patients
from 3 separate institutions. While the BAP1 staining was
interpreted by a single experienced pathologist (AG) who
was blinded to all clinical data, the 3 cohorts were from different
institutions and had slightly different patient characteristics.
While the study patients all underwent surgery with curative
intent, there may be differences in selection criteria for curative
surgery and the use of adjuvant therapy at the different institu-
tions. The fact that the study only included patients who were
candidates for surgical resection with curative intent, as well as
the potential for different selection criteria for treatment
between institutions and surgeons, raises the possibility of
selection bias. Other limitations of this study include its retro-
spective nature and the fact that IHC was performed on TMA
rather than whole sections for many cases and therefore may
have missed heterogeneous staining.
In conclusion, we report an incidence of negative IHC
staining for BAP1 in cholangiocarcinoma of 26% which is
keeping with the reported incidence of BAP1 double hit inac-
tivation as detected by molecular means of 22.2 to 25%.3,21 We
suggest that there is a strong trend toward improved survival for
BAP1 IHC negative cholangiocarcinomas but this trend just
failed to reach statistical significance (P¼ 0.059) even in our
BAP1 in Cholangiocarcinomalarge cohort of 211 resected cholangiocarcinomas. Other than
for some association with higher histological grade, larger size,
and absence of vascular space invasion, we could not identify a
www.md-journal.com | 7
strong clinical or morphological phenotype for BAP1 IHC
negative tumors undergoing surgery with curative intent.
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